Market Overview

UPDATE: Morgan Stanley Reiterates on CVS/Caremark Following Acquisition of Coram

Share:
Related CVS
How The Street Is Reacting To The Aetna-Humana Deal
Consumer Staple ETFs Remain Steady In 2015
Walgreens To Report Q3 Amid Industry Consolidation (Investor's Business Daily)

In a report published Friday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Overweight rating on CVS/Caremark Corporation (NYSE: CVS), but removed the $65.00 price target.

In the report, Morgan Stanley noted, “CVS' $2.1 billion acquisition of Coram, Apria's home infusion business should help solidify CVS' position in the HC continuum and in enhancing its relationships with health systems and ACOs in our view. Importantly, we don't think deal stands in way of supply chain/sourcing partnership.”

CVS/Caremark closed on Wednesday at $66.76.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2015OppenheimerInitiates Coverage onOutperform
Jun 2015Cowen & CompanyMaintainsOutperform
Jun 2015MacquarieInitiates Coverage onOutperform

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

Around the Web, We're Loving...

Get Benzinga's Newsletters